DIVA Laboratories, Ltd (4153) Fair Value & Analysis
Healthcare · TW · Market cap 1.8B TWD
Fair value as of: Jul 21, 2026
From 24 valuation models · updated 20 days ago
Share price +6.8% over the past month.
A solid business, but screening 26% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (30.69 TWD). The favourable scenario is already priced in.
- Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 20.19 TWD – 55.44 TWD · fair‑value band 18.19 TWD – 30.69 TWD · the 33.00 TWD price screens above the 24.44 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
DIVA Laboratories, Ltd (4153) currently trades at 33.00 TWD, while our model-based Fair Value estimate is 24.44 TWD, implying the stock looks roughly 25.9% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, DIVA Laboratories, Ltd generated revenue of 885M TWD at a net margin of 10.2%. Revenue grew 7.6% year over year. It earns a return on equity of 9.5%. The balance sheet holds a net cash position of 346M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 18.19 TWD (bear case) to 30.69 TWD (bull case); at 33.00 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -26%, 4153 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (32.65 TWD) versus Asset-Based (11.75 TWD). Highest evidence: Residual Income (76).
Notify me when 4153 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays.
Full company description
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DIVA Laboratories, Ltd reported revenue of 869M TWD in FY2025 versus 712M TWD in FY2021, a compound +5.1%/yr. Reported net income was 90.5M TWD in FY2025, compounding +42.7%/yr from FY2021.
4153 screens 26% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare DIVA Laboratories, Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DIVA Laboratories, Ltd (4153) overvalued or undervalued?
What is the fair value of 4153?
What is the quality score of 4153?
What is the revenue of DIVA Laboratories, Ltd (4153)?
What is the net profit margin of 4153?
Does DIVA Laboratories, Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DIVA Laboratories, Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.